Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0095 | 1 | 1 |
Loa Loa (eye worm) | brahma associated protein | 0.0095 | 1 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.3525 | 0.3525 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0095 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0095 | 1 | 1 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.3525 | 0.3525 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.0095 | 1 | 0.5 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.0095 | 1 | 0.5 |
Chlamydia trachomatis | SWIB complex protein | 0.0095 | 1 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0095 | 1 | 0.5 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.3525 | 0.3525 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0095 | 1 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0095 | 1 | 0.5 |
Schistosoma mansoni | brg-1 associated factor | 0.0095 | 1 | 1 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0095 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.3525 | 0.3525 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0095 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0095 | 1 | 1 |
Echinococcus granulosus | SWI:SNF matrix associated | 0.0095 | 1 | 0.5 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0095 | 1 | 0.5 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0095 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0095 | 1 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.0095 | 1 | 0.5 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.0095 | 1 | 1 |
Brugia malayi | brahma associated protein 60 kDa | 0.0095 | 1 | 1 |
Onchocerca volvulus | 0.0095 | 1 | 0.5 | |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0095 | 1 | 0.5 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0095 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 14.1254 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 20.5962 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PubChem BioAssay. qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.